Skip to content

Webinar: Assessment of drug-induced structural toxicity in human iPSC-derived cardiomyocytes

Ncardia author image

By Brigitta Szabó, MD, PhD candidate

How to get a more precise understanding of compounds' cardiac safety with human iPSC-derived cardiomyocytes and high-content imaging

Human induced pluripotent stem cell(iPSC)-derived cardiomyocytes can serve as novel, scalable human-based alternatives to traditional models in the field of safety pharmacology, as well as in the preclinical stages of the drug discovery pipeline. Significant progress has already been made towards validating the use of iPSC-derived cardiomyocytes in electrophysiology assays for predicting the clinical potential of arrhythmia, one of the most common cardiac adverse drug effects. However, for other parameters with potential clinical predictive value such as structural toxicity, further optimization and standardization is still warranted.
In this webinar, our PhD candidate Brigitta has presented a predictive high content imaging method in combination with multiparametric analysis algorithms, to perform structural cardiotoxicity screenings with human iPSC-derived cardiomyocytes.

In this webinar you will learn:

  • How human iPSC-derived cardiomyocytes can facilitate more precise in vitro cardiac safety assessment.

  • The correlation between structural and functional cardiotoxicity.

  • The added value of assessing compound induced morphological changes to understand the mechanisms underlying cardiotoxic effects.


Fill in the form below to watch the replay: